Boston Scientific (NYSE:BSX) today claimed a win in its global tussle with Edwards Lifesciences (NYSE:EW) over transcatheter aortic valve replacement patents.
It’s the latest development in a long-running battle being fought on multiple legal fronts over the companies’ respective TAVR patent portfolios. In March 2017, a German court issued a mixed decision in the spat, less than a week after a U.K. patent court handed down a similar decision.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,